ARIAD PHARMACEUTICALS INC (ARIA) is a publicly traded company in the Unknown sector. Across all available filings, 34 corporate insiders have executed 859 transactions totaling $62.0M, demonstrating a bearish sentiment with -$42.6M in net insider flow. The most recent transaction on Feb 16, 2017 involved a transaction of 53,173 shares valued at $0.
No significant insider buying has been recorded for ARIA in the recent period.
No significant insider selling has been recorded for ARIA in the recent period.
Based on recent SEC filings, insider sentiment for ARIA is bearish with an Insider Alignment Score of 16/100 and a net flow of -$42.6M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at ARIAD PHARMACEUTICALS INC (ARIA) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 34 insiders are actively trading ARIA stock, having executed 859 transactions in the past 90 days. The most active insider is Harvey J. M. D. Berger (Executive), who has made 130 transactions totaling $28.9M.
Get notified when executives and directors at ARIA file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Feb 16, 2017 | J. Denner Alexander | Executive | Disposition | 53,173 | $N/A | $0 | |
| Feb 16, 2017 | J. Denner Alexander | Executive | Disposition | 7,798,665 | $N/A | $0 | |
| Feb 16, 2017 | J. Denner Alexander | Executive | Disposition | 5,051,335 | $N/A | $0 | |
| Feb 16, 2017 | Singh Soni Manmeet | Executive | Disposition | 3,273 | $N/A | $0 | |
| Feb 16, 2017 | Protopapas Anna | Executive | Disposition | 41,910 | $N/A | $0 | |
| Feb 16, 2017 | Panayiotopoulos Paris | Executive | Disposition | 159,378 | $N/A | $0 | |
| Feb 16, 2017 | M. Bollag Daniel | Executive | Disposition | 126,352 | $N/A | $0 | |
| Feb 16, 2017 | G. Riedel Norbert | Executive | Disposition | 139,867 | $N/A | $0 | |
| Feb 16, 2017 | M. Cole Hugh | Executive | Disposition | 42,834 | $N/A | $0 | |
| Feb 16, 2017 | Lyn Herron Jennifer | Executive | Disposition | 450 | $N/A | $0 | |
| Feb 16, 2017 | Bickerstaff George | Executive | Disposition | 18,008 | $N/A | $0 | |
| Feb 16, 2017 | Haimovitz Jules | Executive | Disposition | 18,008 | $N/A | $0 | |
| Feb 16, 2017 | P. Clackson Timothy | Executive | Disposition | 219,867 | $N/A | $0 | |
| Feb 16, 2017 | P. Clackson Timothy | Executive | Disposition | 577 | $N/A | $0 | |
| Feb 16, 2017 | J. Schlesinger Sarah | Executive | Disposition | 55,508 | $N/A | $0 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 290 | $52.3M | 59.0% |
Payment(F) | 80 | $14.9M | 16.9% |
Exercise(M) | 332 | $11.6M | 13.0% |
Purchase(P) | 34 | $9.7M | 10.9% |
Disposition(D) | 16 | $141.0K | 0.2% |
Gift(G) | 36 | $0 | 0.0% |
Award(A) | 71 | $0 | 0.0% |
Insider selling pressure at ARIAD PHARMACEUTICALS INC has increased, with 34 insiders executing 859 transactions across all time. Total sales of $52.3M significantly outpace purchases of $9.7M, resulting in a net outflow of $42.6M. This selling activity appears largely discretionary, which may warrant closer attention from investors.